Pharmaceutical company AmerisourceBergen Corporation will pay $625 million after it allegedly harvested “overfill” from FDA-approved sterile vials of cancer medication and repackaged the drugs in its own pre-filled syringes in non-sterile conditions, according to the Justice Department. The company, which sought to profit off of the excess product contained in the sterile drug vials, was accused of breaking the sterility of the vials by opening them and pooling them together for repackaging in syringes. It then sent “millions” of syringes out for distribution to “vulnerable” cancer patients, prosecutors allege. The Justice Department also claims the company gave doctors “kickbacks” to make them purchase the pre-filled syringes. The alleged scheme was brought to light by three whistleblowers in civil-action lawsuits. The whistleblowers will each receive $93,089,441. “ABC placed corporate profits over patients’ needs, endangering the health of vulnerable cancer patients,” said U.S. Attorney Richard Donoghue.